0001609351-17-000102.txt : 20170911
0001609351-17-000102.hdr.sgml : 20170911
20170911161548
ACCESSION NUMBER: 0001609351-17-000102
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170907
FILED AS OF DATE: 20170911
DATE AS OF CHANGE: 20170911
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Faga Daniel
CENTRAL INDEX KEY: 0001673528
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36819
FILM NUMBER: 171079156
MAIL ADDRESS:
STREET 1: 3737 MARKET STREET
STREET 2: SUITE 1300
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Spark Therapeutics, Inc.
CENTRAL INDEX KEY: 0001609351
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 462654405
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3737 MARKET STREET
STREET 2: SUITE 1300
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
BUSINESS PHONE: 888-772-7560
MAIL ADDRESS:
STREET 1: 3737 MARKET STREET
STREET 2: SUITE 1300
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
4
1
wf-form4_150516093442742.xml
FORM 4
X0306
4
2017-09-07
0
0001609351
Spark Therapeutics, Inc.
ONCE
0001673528
Faga Daniel
3737 MARKET STREET
SUITE 1300
PHILADELPHIA
PA
19104
0
1
0
0
Chief Business Officer
Common Stock
2017-09-07
4
M
0
3000
37.62
A
3000
D
Common Stock
2017-09-07
4
S
0
1500
85
D
1500
D
Common Stock
2017-09-07
4
S
0
1500
85.03
D
0
D
Employee Stock Option (right to buy)
37.62
2017-09-07
4
M
0
3000
0
D
2026-05-01
Common Stock
3000.0
145000
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2017.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.00 to $85.04, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
25% vested May 2, 2017 and the remainder vests in equal quarterly installments over the following three years.
/s/ Joseph W. La Barge, attorney-in-fact for Daniel R. Faga
2017-09-11